Kraig Biocraft Laboratories, Inc. (Trading Symbol: KBLB) is a fully reporting biotechnology company focused on the development and commercialization of spider silks. Kraig possesses the exclusive right to use patented spider silk gene sequences in silkworms, which is the first feasible way to mass produce these fibers cost effectively and responsibly. Spider silk is biodegradable.
The company uses genetic engineering and recombinant DNA technology to produce recombinant spider silk based fibers on an industrial scale. Kraig Labs successfully synthesized the DNA for a highly complex set of spider silk protein construct designs using a combination of approaches that aim to accelerate the pace of its research and production and decrease cost. The new spider silk designs could produce new silk fibers with more strength and flexibility than the previous generation of recombinant spider silk.
Kraig Biocraft's spider silks have applications in textiles and performance polymers. Initially developed for specialized military applications, Kraig has plans for materials made from recombinant spider silk to eventually be available on the global market for high performance textiles and apparel.
Plans to bring to market the first fabrics made from spider silk were announced in 2019 by Kraig Biocraft Laboratories and its partner, the textile company Polartec. In joint development since 2016, Polartec and Kraig are applying the performance characteristics of spider silk into yarns for military-grade textiles.
- Synthetic biologySynthetic biology is a multidisciplinary area of research that seeks to create new biological parts, devices, and systems, or to redesign systems that are already found in nature to have new abilities.
- BiotechnologyBiotechnology in a broad sense includes the use of living systems and organisms, as well as their parts for the development or production of products.